Investment to develop pain therapy
A pain drug development company spun out of The University of Queensland has received a $3.25 million investment commitment to develop its innovative pain therapy.
Spinifex Pharmaceuticals, an emerging biotechnology company specialising in the development of therapeutics for the treatment of neuropathic pain, has attracted investment from a syndicate including Symbiosis Group Limited, Melbourne-based GBS Venture Partners Limited and Uniseed.
Spinifex's core technology relates to the discovery (made by University of Queensland researchers led by Professor Maree Smith) of a novel pathway for the treatment of neuropathic pain. Professor Smith's group successfully validated this pathway using small molecules in well-defined animal models of neuropathic pain.
A simple finger prick can be used to diagnose Alzheimer's
A new study is paving the way for a more accessible method of Alzheimer's testing, requiring...
Experimental blood test detects early-stage pancreatic cancer
The new test works by detecting two sugars — CA199.STRA and CA19-9 — that are...
Biomarkers for dementia vary with time of day
Biomarkers used to diagnose Alzheimer's, including a promising marker for early diagnosis of...
